RxDoctor Payments Data

John Rapacz, MD

Family Medicine · Midwest City, OKNPI 1508858853

Payments from drug & device makers

$3,810in general payments, 2019–2025

Across 207 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$830
  • AstraZeneca$536
  • Novo Nordisk$381
  • Lilly USA, LLC$332
  • Bayer$298
  • GSK$212
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,810 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$268,318
Medicare patients
468
Services billed
4,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate127$114,401
OzempicSemaglutide83$110,764
FarxigaDapagliflozin Propanediol80$72,685
RybelsusSemaglutide45$71,945
MounjaroTirzepatide40$70,052
JardianceEmpagliflozin45$59,876
TrulicityDulaglutide27$39,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$38,878
EliquisApixaban23$28,065
LinzessLinaclotide15$10,514
PremarinEstrogens, Conjugated17$8,719
Breo ElliptaFluticasone/Vilanterol14$8,409
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$6,005
Potassium Chloride173$4,335
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid32$4,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$381$182,709128 claims
Lilly USA, LLCMounjaro, Trulicity$332$109,13267 claims
AstraZenecaFarxiga$536$72,68580 claims
Boehringer IngelheimJardiance$171$59,87645 claims
GSKTrelegy Ellipta, Breo Ellipta$212$47,28752 claims
PfizerEliquis, Premarin$93$36,78440 claims
AbbVieLinzess, Synthroid$830$12,57351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →